SCNI
Scinai Immunotherapeutics Ltd.
Set alert
- YTD
- -93.38%
- 1 year
- -96.77%
- Open
- 0.545
- Prev close
- 0.5185
- Mkt cap
- 1.24M
- Vol
- 52.95K
- Avg vol
- 2.15M
- EPS
- 28.07
- P/E
- 0.02
- Div yield
- 0.00%
More statistics
- Low
- 0.47
- High
- 0.545
- Forward P/E
- 0.00
- Beta
- 2.46
- Short ratio
- 0.09
- Inst. own
- 2.36%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 3.41
- 200-d avg
- 3.91
- 1y target
- 0.00
Key statistics
- Market cap
- 2.86M
- Enterprise value
- 10.13B
- Trailing P/E
- 1.40
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 10.06
- Price / book
- 0.00
- EPS (TTM)
- 2.40
- Beta
- 2.46
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 284.00K
- Revenue growth
- 0.00%
- Free cash flow
- -3.79M
- Total cash
- 3.08M
- Total debt
- 20.82M
- Return on equity
- 0.00%
- Shares outstanding
- 853.00K
- Short % of float
- 0.88%
- 50-day average
- 3.41
- 200-day average
- 3.91
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 22, 2024 | Sep 1, 2024 | 0.00 | 8.40 | — | — |
| Aug 15, 2024 | Jun 1, 2024 | 0.00 | -3.57 | — | — |
| Jul 2, 2024 | Mar 1, 2024 | 0.00 | -4.00 | — | — |
| May 15, 2024 | Dec 1, 2023 | 0.00 | -240.00 | — | — |
| Oct 31, 2023 | Sep 1, 2023 | 0.00 | -6.60 | — | — |
About Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- scinai.com
News
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed Financing
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement
- Why Is Scinai Immunotherapeutics Stock Gaining Tuesday?
Your note
Sign in to keep a note on SCNI — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Rhumbline Advisers | 0.19% | 1,653 | 5.54K | Sep 29, 2024 |
| Morgan Stanley | 0.03% | 255 | 854 | Sep 29, 2024 |
| Aspire Private Capital, LLC | 0.00% | 32 | 107 | Sep 29, 2024 |
| Credit Agricole S.A. | 0.00% | 42 | 140 | Sep 29, 2024 |
| UBS Group AG | 0.00% | 30 | 100 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR Portfolio Developed World ex-US ETF | 0.00% | 2 | 6 | Sep 29, 2024 |